关注
alastair greystoke
alastair greystoke
在 newcastle.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer
MG Krebs, R Sloane, L Priest, L Lancashire, JM Hou, A Greystoke, ...
Journal of clinical oncology 29 (12), 1556-1563, 2011
10512011
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer
JM Hou, MG Krebs, L Lancashire, R Sloane, A Backen, RK Swain, ...
Journal of Clinical Oncology 30 (5), 525-532, 2012
9822012
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
CL Hodgkinson, CJ Morrow, Y Li, RL Metcalf, DG Rothwell, F Trapani, ...
Nature medicine 20 (8), 897-903, 2014
7982014
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy
JM Hou, A Greystoke, L Lancashire, J Cummings, T Ward, R Board, ...
The American journal of pathology 175 (2), 808-816, 2009
2882009
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
RE Board, AM Wardley, JM Dixon, AC Armstrong, S Howell, L Renshaw, ...
Breast cancer research and treatment 120, 461-467, 2010
2362010
Update on tubulin-binding agents
G Attard, A Greystoke, S Kaye, J De Bono
Pathologie Biologie 54 (2), 72-84, 2006
2112006
ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK …
BC Cho, DW Kim, A Bearz, SA Laurie, M McKeage, G Borra, K Park, ...
Journal of Thoracic Oncology 12 (9), 1357-1367, 2017
1922017
Biomarkers of apoptosis
TH Ward, J Cummings, E Dean, A Greystoke, JM Hou, A Backen, ...
British journal of cancer 99 (6), 841-846, 2008
1592008
Biomarker method validation in anticancer drug development
J Cummings, TH Ward, A Greystoke, M Ranson, C Dive
British journal of pharmacology 153 (4), 646-656, 2008
1542008
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
OA Khan, M Gore, P Lorigan, J Stone, A Greystoke, W Burke, ...
British journal of cancer 104 (5), 750-755, 2011
1472011
The National Lung Matrix Trial of personalized therapy in lung cancer
G Middleton, P Fletcher, S Popat, J Savage, Y Summers, A Greystoke, ...
Nature 583 (7818), 807-812, 2020
1342020
Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer
RE Board, VS Williams, L Knight, J Shaw, A Greystoke, M Ranson, C Dive, ...
Annals of the New York Academy of Sciences 1137 (1), 98-107, 2008
1312008
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014
B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ...
Clinical cancer research 21 (15), 3412-3419, 2015
1272015
Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis
MJ Ahn, CH Chiu, Y Cheng, JY Han, SB Goldberg, A Greystoke, ...
Journal of Thoracic Oncology 15 (4), 637-648, 2020
1102020
DNA methylation in circulating tumour DNA as a biomarker for cancer
RE Board, L Knight, A Greystoke, FH Blackhall, A Hughes, C Dive, ...
Biomarker Insights 2, 117727190700200003, 2007
912007
Optimisation of circulating biomarkers of cell death for routine clinical use
A Greystoke, J Cummings, T Ward, K Simpson, A Renehan, F Butt, ...
Annals of oncology 19 (5), 990-995, 2008
852008
Alternative splicing in lung cancer
AO Coomer, F Black, A Greystoke, J Munkley, DJ Elliott
Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1862 (11-12 …, 2019
752019
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
G Mak, JC Soria, SP Blagden, R Plummer, RA Fleming, N Nebot, J Zhang, ...
British journal of cancer 120 (10), 975-981, 2019
662019
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
A Greystoke, JPB O'Connor, K Linton, MB Taylor, J Cummings, T Ward, ...
British journal of cancer 104 (4), 719-725, 2011
562011
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
DA Fennell, A King, S Mohammed, A Greystoke, S Anthony, C Poile, ...
The Lancet Oncology 23 (3), 374-381, 2022
492022
系统目前无法执行此操作,请稍后再试。
文章 1–20